Description
Overview
AT-rich interactive domain-containing protein 1A (ARID1A) is a critical component of the SWI/SNF chromatin remodeling complex, which regulates gene expression by modulating chromatin structure and accessibility. ARID1A plays essential roles in transcriptional regulation, DNA damage repair, and the maintenance of genomic stability. It acts as a tumor suppressor, with frequent inactivating mutations observed in a variety of cancers, including ovarian clear cell carcinoma, endometrial cancer, and gastric cancer. Loss of ARID1A disrupts chromatin remodeling, leading to altered transcriptional programs, impaired DNA damage responses, and increased sensitivity to epigenetic and DNA repair inhibitors. Notably, synthetic lethality with EZH2 and ATR inhibitors has emerged as a promising therapeutic strategy, positioning ARID1A as a key biomarker and vulnerability in precision oncology.
The AlphaLISA
SureFire Ultra
Human and Mouse Total ARID1A Detection Kit is a sandwich immunoassay for the quantitative detection of total ARID1A in cellular lysates, using Alpha Technology.
Formats:
The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA
SureFire Ultra
kits are compatible with:
Cell and tissue lysates
Antibody modulators
Biotherapeutic antibodies
AlphaLISA
SureFire Ultra
kits can be used for:
Cellular kinase assays
Receptor activation studies
High-throughput screening for preclinical studies
How it works
Total-AlphaLISA
SureFire Ultra
assay principle
The Total-AlphaLISA
SureFire Ultra
assay measures the expression level of a protein target in a cell lysate.
The Total-AlphaLISA
SureFire Ultra
assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
Total-AlphaLISA
SureFire Ultra
two-plate assay protocol
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA
SureFire Ultra
detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Total-AlphaLISA
SureFire Ultra
one-plate assay protocol
Detection of Total target protein with AlphaLISA
SureFire Ultra
reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA
SureFire Ultra
quality.
Assay versatility
Versatility of Total ARID1A assay in various cell lines
Adherent cells were seeded at 40,000 cells/well in a 96-well culture plate in complete medium and incubated overnight at 37°C, 5% CO2. Cells were lysed with 100 µL of Lysis Buffer.
Suspension cells were seeded at 400,000 cells/well in a 96-well culture plate in HBSS + 0.1% BSA and lysed with 100 µL of Lysis Buffer.
ARID1A levels were evaluated by AlphaLISA
SureFire Ultra.
For the detection step, 10 µL of cell lysate (approximately 4,000 adherent cells or 40,000 suspension cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
